MX336321B - 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer. - Google Patents

99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer.

Info

Publication number
MX336321B
MX336321B MX2010003829A MX2010003829A MX336321B MX 336321 B MX336321 B MX 336321B MX 2010003829 A MX2010003829 A MX 2010003829A MX 2010003829 A MX2010003829 A MX 2010003829A MX 336321 B MX336321 B MX 336321B
Authority
MX
Mexico
Prior art keywords
breast cancer
radiopharmaceutical
bombesin
tat
mtc
Prior art date
Application number
MX2010003829A
Other languages
Spanish (es)
Other versions
MX2010003829A (en
Inventor
Guillermina Ferro Flores
Flor De María Ramírez De La Cruz
Clara Leticia Santos Cuevas
Original Assignee
Inst Nac De Investigaciones Nucleares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nac De Investigaciones Nucleares filed Critical Inst Nac De Investigaciones Nucleares
Priority to MX2010003829A priority Critical patent/MX336321B/en
Publication of MX2010003829A publication Critical patent/MX2010003829A/en
Publication of MX336321B publication Critical patent/MX336321B/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention refers to a novel radiopharmaceutical of Technetium-99m-N2S2-TAT (49- 57)-Lys3-Bombesin as an agent for the diagnosis of breast cancer by gammagraphic images, which is able to detect in vivo the overexpression of GRP receptors in MCF7 and MDA-MB231 cells of human breast cancer. Likewise, due to the internalization of the Tc-99m radionuclide into the PC-3 cells of prostate cancer and MCF7 and MDA-MB231 of breast cancer, the radiopharmaceutical may be used as a therapeutic agent. The purpose of the present invention is to provide a novel specific radiopharmaceutical (molecular target radiopharmaceutical) for a diagnosis and possible therapy of breast cancer, which is totally different from those currently available on the market.
MX2010003829A 2010-04-08 2010-04-08 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer. MX336321B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2010003829A MX336321B (en) 2010-04-08 2010-04-08 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010003829A MX336321B (en) 2010-04-08 2010-04-08 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer.

Publications (2)

Publication Number Publication Date
MX2010003829A MX2010003829A (en) 2011-10-31
MX336321B true MX336321B (en) 2016-01-12

Family

ID=45789268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003829A MX336321B (en) 2010-04-08 2010-04-08 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer.

Country Status (1)

Country Link
MX (1) MX336321B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104324394A (en) * 2014-11-05 2015-02-04 成都药航科技有限公司 Molecular probe developer, as well as preparation method and application thereof
RU2720801C1 (en) * 2019-02-11 2020-05-13 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") RADIONUCLIDE DIAGNOSTIC TECHNIQUE FOR BREAST CANCER WITH Her2/neu HYPEREXPRESSION

Also Published As

Publication number Publication date
MX2010003829A (en) 2011-10-31

Similar Documents

Publication Publication Date Title
MX2021003858A (en) Conjugates for treating diseases caused by psma expressing cells.
EA201892668A1 (en) Tc-EDDA / HYNIC-iPSMA AS A RADIO-PHARMACEUTICAL PRODUCT FOR DETECTION OF SUPEREXPRESSION OF A PROSTATSPECIFIC MEMBRANE ANTIGEN
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
EA201290901A1 (en) PHYTOCANNABINOIDS FOR THE TREATMENT OF MALIGNANT TUMOR
MX2021008976A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
EA201290712A1 (en) ALPHA-RADIATING COMPLEXES
MX358517B (en) Methods for determining drug efficacy using cereblon-associated proteins.
MX2013002084A (en) Biomarkers and methods of treatment.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
WO2012068383A3 (en) ncRNA AND USES THEREOF
EA032867B9 (en) Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
SG10201810357WA (en) Ly75 as cancer therapeutic and diagnostic target
NZ606466A (en) Peptide radiotracer compositions
AR090352A1 (en) ANTIBODIES AGAINST BRADICININE B1 RECEIVER LIGANDS
WO2012007783A8 (en) Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
WO2009103741A3 (en) Use of fsh receptor ligands for diagnosis and therapy of cancer
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
GB201103696D0 (en) Technetium labelled peptides
MX336321B (en) 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer.
GB201121914D0 (en) Method for patient selection
WO2010127054A3 (en) Imaging tumor perfusion, and oxidative metabolism using dynamic ace pet in patients with head and neck cancer during radiotherapy
MX340487B (en) Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system.
WO2013188823A3 (en) Cancer prognostic assays